{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T16:42:25Z","timestamp":1777394545119,"version":"3.51.4"},"reference-count":41,"publisher":"SAGE Publications","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAD"],"published-print":{"date-parts":[[2016,8,23]]},"DOI":"10.3233\/jad-160364","type":"journal-article","created":{"date-parts":[[2016,8,16]],"date-time":"2016-08-16T14:36:30Z","timestamp":1471358190000},"page":"351-357","source":"Crossref","is-referenced-by-count":7,"title":["Cerebral White Matter Changes on Therapeutic Response to Rivastigmine in Alzheimer\u2019s Disease"],"prefix":"10.1177","volume":"54","author":[{"given":"Bo-Lin","family":"Ho","sequence":"first","affiliation":[{"name":"Department of Neurology, Kaohsiung Municipal Ta-Tung Hospital, Kaohsiung, Taiwan"},{"name":"Department of Neurology, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi-Hui","family":"Kao","sequence":"additional","affiliation":[{"name":"Department of Neurology, National Taiwan University Hospital, Yun-Lin Branch, Yun-Lin, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mei-Chuan","family":"Chou","sequence":"additional","affiliation":[{"name":"Department of Neurology, Kaohsiung Municipal Ta-Tung Hospital, Kaohsiung, Taiwan"},{"name":"Department of Neurology, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuan-Han","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Neurology, Kaohsiung Municipal Ta-Tung Hospital, Kaohsiung, Taiwan"},{"name":"Department of Neurology, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan"},{"name":"Department of and Master\u2019s Program in Neurology, Faculty of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","reference":[{"key":"10.3233\/JAD-160364_ref1","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s13195-015-0128-z","article-title":"Comprehensive treatment of dementia with Lewy bodies","volume":"7","author":"Boot","year":"2015","journal-title":"Alzheimers Res Ther"},{"key":"10.3233\/JAD-160364_ref2","doi-asserted-by":"crossref","first-page":"17","DOI":"10.2147\/ciia.2007.2.1.17","article-title":"Rivastigmine in the treatment of Alzheimer\u2019s disease: An update","volume":"2","author":"Onor","year":"2007","journal-title":"Clin Interv Aging"},{"key":"10.3233\/JAD-160364_ref3","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1097\/00001756-200502080-00006","article-title":"Empirical evidence of neuroprotection by dual cholinesterase inhibition in Alzheimer\u2019s disease","volume":"16","author":"Venneri","year":"2005","journal-title":"Neuroreport"},{"key":"10.3233\/JAD-160364_ref4","doi-asserted-by":"crossref","first-page":"S48","DOI":"10.1161\/STROKEAHA.108.537704","article-title":"Understanding white matter disease: Imaging-pathological correlations in vascular cognitive impairment","volume":"40","author":"Black","year":"2009","journal-title":"Stroke"},{"key":"10.3233\/JAD-160364_ref5","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s00401-011-0851-x","article-title":"Heterogeneity in age-related white matter changes","volume":"122","author":"Schmidt","year":"2011","journal-title":"Acta Neuropathol"},{"key":"10.3233\/JAD-160364_ref6","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1001\/jamaneurol.2013.1321","article-title":"White matter hyperintensities and cerebral amyloidosis: Necessary and sufficient for clinical expression of Alzheimer disease?","volume":"70","author":"Provenzano","year":"2013","journal-title":"JAMA Neurol"},{"key":"10.3233\/JAD-160364_ref7","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1111\/ene.12546","article-title":"Association between white matter hyperintensity and medial temporal atrophy at various stages of Alzheimer\u2019s disease","volume":"22","author":"Kandiah","year":"2015","journal-title":"Eur J Neurol"},{"key":"10.3233\/JAD-160364_ref8","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1001\/archneur.64.2.266","article-title":"Strategic subcortical hyperintensities in cholinergic pathways and executive function decline in treated Alzheimer patients","volume":"64","author":"Behl","year":"2007","journal-title":"Arch Neurol"},{"key":"10.3233\/JAD-160364_ref9","doi-asserted-by":"crossref","first-page":"277","DOI":"10.2174\/156720507781077313","article-title":"Executive dyscontrol in dementia, with emphasis on subcortical pathology and the role of butyrylcholinesterase","volume":"4","author":"Bullock","year":"2007","journal-title":"Curr Alzheimer Res"},{"key":"10.3233\/JAD-160364_ref10","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1212\/WNL.34.7.939","article-title":"Clinical diagnosis of Alzheimer\u2019s disease: Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer\u2019s Disease","volume":"34","author":"McKhann","year":"1984","journal-title":"Neurology"},{"key":"10.3233\/JAD-160364_ref11","doi-asserted-by":"crossref","first-page":"351","DOI":"10.2214\/ajr.149.2.351","article-title":"MR signal abnormalities at 1.5 T in Alzheimer\u2019s dementia and normal aging","volume":"149","author":"Fazekas","year":"1987","journal-title":"AJR Am J Roentgenol"},{"key":"10.3233\/JAD-160364_ref12","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1161\/01.STR.32.6.1318","article-title":"A new rating scale for age-related white matter changes applicable to MRI and CT","volume":"32","author":"Wahlund","year":"2001","journal-title":"Stroke"},{"key":"10.3233\/JAD-160364_ref13","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/0022-3956(75)90026-6","article-title":"Mini-mental state. A practical method for grading the cognitive state of patients for the clinician","volume":"12","author":"Folstein","year":"1975","journal-title":"J Psychiatr Res"},{"key":"10.3233\/JAD-160364_ref14","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1159\/000066024","article-title":"Cutoff scores of the cognitive abilities screening instrument, Chinese version in screening of dementia","volume":"14","author":"Lin","year":"2002","journal-title":"Dement Geriatr Cogn Disord"},{"key":"10.3233\/JAD-160364_ref15","doi-asserted-by":"crossref","first-page":"2308","DOI":"10.1212\/WNL.44.12.2308","article-title":"The Neuropsychiatric Inventory: Comprehensive assessment of psychopathology in dementia","volume":"44","author":"Cummings","year":"1994","journal-title":"Neurology"},{"key":"10.3233\/JAD-160364_ref16","doi-asserted-by":"crossref","first-page":"2412","DOI":"10.1212\/WNL.43.11.2412-a","article-title":"The Clinical Dementia Rating (CDR): Current version and scoring rules","volume":"43","author":"Morris","year":"1993","journal-title":"Neurology"},{"key":"10.3233\/JAD-160364_ref17","doi-asserted-by":"crossref","first-page":"391","DOI":"10.3233\/JAD-2010-100936","article-title":"Plasma concentration of donepezil to the therapeutic response of Alzheimer\u2019s disease in Taiwanese","volume":"23","author":"Yang","year":"2011","journal-title":"J Alzheimers Dis"},{"key":"10.3233\/JAD-160364_ref18","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1212\/WNL.0000000000001376","article-title":"Differences in Alzheimer disease clinical trial outcomes based on age of the participants","volume":"84","author":"Schneider","year":"2015","journal-title":"Neurology"},{"key":"10.3233\/JAD-160364_ref19","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1186\/1471-2377-12-134","article-title":"Functional response to cholinesterase inhibitor therapy in a naturalistic Alzheimer\u2019s disease cohort","volume":"12","author":"Wattmo","year":"2012","journal-title":"BMC Neurol"},{"key":"10.3233\/JAD-160364_ref20","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1136\/jnnp.2004.043539","article-title":"Predicting the outcome of cholinesterase inhibitor treatment in Alzheimer\u2019s disease","volume":"76","author":"Connelly","year":"2005","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.3233\/JAD-160364_ref21","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1001\/archneur.58.3.417","article-title":"Response of patients with Alzheimer disease to rivastigmine treatment is predicted by the rate of disease progression","volume":"58","author":"Farlow","year":"2001","journal-title":"Arch Neurol"},{"key":"10.3233\/JAD-160364_ref22","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/alzrt85","article-title":"Predictors of long-term cognitive outcome in Alzheimer\u2019s disease","volume":"3","author":"Wattmo","year":"2011","journal-title":"Alzheimers Res Ther"},{"key":"10.3233\/JAD-160364_ref23","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1001\/archneur.63.2.246","article-title":"Association of white matter hyperintensity volume with decreased cognitive functioning: The Framingham Heart Study","volume":"63","author":"Au","year":"2006","journal-title":"Arch Neurol"},{"key":"10.3233\/JAD-160364_ref24","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1001\/archneurol.2012.1527","article-title":"Regional white matter hyperintensity volume, not hippocampal atrophy, predicts incident Alzheimer disease in the community","volume":"69","author":"Brickman","year":"2012","journal-title":"Arch Neurol"},{"key":"10.3233\/JAD-160364_ref25","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.1212\/01.wnl.0000249119.95747.1f","article-title":"Extent and distribution of white matter hyperintensities in normal aging, MCI, and AD","volume":"67","author":"Yoshita","year":"2006","journal-title":"Neurology"},{"key":"10.3233\/JAD-160364_ref26","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1159\/000330019","article-title":"White matter disease independently predicts progression from mild cognitive impairment to Alzheimer\u2019s disease in a clinic cohort","volume":"31","author":"Prasad","year":"2011","journal-title":"Dement Geriatr Cogn Disord"},{"key":"10.3233\/JAD-160364_ref27","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1002\/gps.1799","article-title":"Cerebral white matter changes and rate of progression of dementia during cholinesterase inhibitor treatment: A retrospective cohort study","volume":"22","author":"Devine","year":"2007","journal-title":"Int J Geriatr Psychiatry"},{"key":"10.3233\/JAD-160364_ref28","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000078625","article-title":"Efficacy of donepezil treatment in Alzheimer patients with and without subcortical vascular lesions","volume":"72","author":"Blasko","year":"2004","journal-title":"Pharmacology"},{"key":"10.3233\/JAD-160364_ref29","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1159\/000085069","article-title":"Do vascular lesions and related risk factors influence responsiveness to donepezil chloride in patients with Alzheimer\u2019s disease?","volume":"20","author":"Fukui","year":"2005","journal-title":"Dement Geriatr Cogn Disord"},{"key":"10.3233\/JAD-160364_ref30","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1016\/S0140-6736(96)90608-X","article-title":"15-year longitudinal study of blood pressure and dementia","volume":"347","author":"Skoog","year":"1996","journal-title":"Lancet"},{"key":"10.3233\/JAD-160364_ref31","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1007\/s00415-006-0238-4","article-title":"Brain atrophy and white matter hyperintensity change in older adults and relationship to blood pressure. Brain atrophy, WMH change and blood pressure","volume":"254","author":"Firbank","year":"2007","journal-title":"J Neurol"},{"key":"10.3233\/JAD-160364_ref32","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1046\/j.1468-1331.2000.00046.x","article-title":"An efficacy and safety analysis of Exelon in Alzheimer\u2019s disease patients with concurrent vascular risk factors","volume":"7","author":"Kumar","year":"2000","journal-title":"Eur J Neurol"},{"key":"10.3233\/JAD-160364_ref33","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1111\/j.1742-1241.2002.tb11377.x","article-title":"Rivastigmine in patients with Alzheimer\u2019s disease and concurrent hypertension","volume":"56","author":"Erkinjuntti","year":"2002","journal-title":"Int J Clin Pract"},{"key":"10.3233\/JAD-160364_ref34","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1111\/j.1742-1241.2003.tb10609.x","article-title":"Potential long-term effects of rivastigmine on disease progression may be linked to drug effects on vascular changes in Alzheimer brains","volume":"57","author":"Erkinjuntti","year":"2003","journal-title":"Int J Clin Pract"},{"key":"10.3233\/JAD-160364_ref35","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1097\/00001756-200201210-00020","article-title":"Cerebral blood flow and cognitive responses to rivastigmine treatment in Alzheimer\u2019s disease","volume":"13","author":"Venneri","year":"2002","journal-title":"Neuroreport"},{"key":"10.3233\/JAD-160364_ref36","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1097\/FPC.0b013e32832f8c17","article-title":"Progression from mild cognitive impairment to Alzheimer\u2019s disease: Effects of sex, butyrylcholinesterase genotype, and rivastigmine treatment","volume":"19","author":"Ferris","year":"2009","journal-title":"Pharmacogenet Genomics"},{"key":"10.3233\/JAD-160364_ref37","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1002\/gps.1331","article-title":"Hypertension, white matter change and response to cholinesterase inhibitors in Alzheimer\u2019s disease","volume":"20","author":"Connelly","year":"2005","journal-title":"Int J Geriatr Psychiatry"},{"key":"10.3233\/JAD-160364_ref38","first-page":"161","article-title":"Genetic characteristics of dementia in Taiwan","volume":"15","author":"Chen","year":"2006","journal-title":"Acta Neurol Taiwan"},{"key":"10.3233\/JAD-160364_ref39","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1097\/01.wad.0000213880.93665.c7","article-title":"Relationship between the efficacy of rivastigmine and apolipoprotein E (epsilon4) in patients with mild to moderately severe Alzheimer disease","volume":"20","author":"Blesa","year":"2006","journal-title":"Alzheimer Dis Assoc Disord"},{"key":"10.3233\/JAD-160364_ref40","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1212\/WNL.0000000000001379","article-title":"Effects of vascular risk factors and APOE \u025b4 on white matter integrity and cognitive decline","volume":"84","author":"Wang","year":"2015","journal-title":"Neurology"},{"key":"10.3233\/JAD-160364_ref41","doi-asserted-by":"crossref","first-page":"857","DOI":"10.3233\/JAD-2012-120109","article-title":"Concentrations of rivastigmine and NAP 226-90 and the cognitive response in Taiwanese Alzheimer\u2019s disease patients","volume":"31","author":"Chou","year":"2012","journal-title":"J Alzheimers Dis"}],"container-title":["Journal of Alzheimer's Disease"],"original-title":[],"link":[{"URL":"https:\/\/content.iospress.com\/download?id=10.3233\/JAD-160364","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T10:03:37Z","timestamp":1777370617000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/full\/10.3233\/JAD-160364"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8,23]]},"references-count":41,"journal-issue":{"issue":"1"},"URL":"https:\/\/doi.org\/10.3233\/jad-160364","relation":{},"ISSN":["1387-2877","1875-8908"],"issn-type":[{"value":"1387-2877","type":"print"},{"value":"1875-8908","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,8,23]]}}}